0
0
0
Prescription Pricing for the People Act of 2023
3/14/2024, 11:04 AM
Summary of Bill S 113
The Prescription Pricing for the People Act of 2023, also known as Bill 118 s 113, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to address the rising costs of prescription drugs and make them more affordable for all Americans.
One of the key provisions of the bill is the establishment of a Prescription Drug Affordability Board, which would be responsible for setting limits on the prices of prescription medications. This board would take into account factors such as the cost of production, research and development expenses, and the need for a reasonable profit margin for pharmaceutical companies.
Additionally, the bill aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing their medications. This would help consumers better understand why certain drugs are priced the way they are and hold companies accountable for any unjustified price increases. Furthermore, the Prescription Pricing for the People Act of 2023 includes measures to promote competition in the prescription drug market, such as allowing the importation of cheaper medications from other countries and encouraging the development of generic alternatives to brand-name drugs. Overall, this bill seeks to address the issue of skyrocketing prescription drug prices and ensure that all Americans have access to affordable medications. It is currently being debated in Congress, with supporters arguing that it is necessary to protect consumers from price gouging by pharmaceutical companies, while opponents raise concerns about potential negative impacts on innovation and research in the industry.
One of the key provisions of the bill is the establishment of a Prescription Drug Affordability Board, which would be responsible for setting limits on the prices of prescription medications. This board would take into account factors such as the cost of production, research and development expenses, and the need for a reasonable profit margin for pharmaceutical companies.
Additionally, the bill aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing their medications. This would help consumers better understand why certain drugs are priced the way they are and hold companies accountable for any unjustified price increases. Furthermore, the Prescription Pricing for the People Act of 2023 includes measures to promote competition in the prescription drug market, such as allowing the importation of cheaper medications from other countries and encouraging the development of generic alternatives to brand-name drugs. Overall, this bill seeks to address the issue of skyrocketing prescription drug prices and ensure that all Americans have access to affordable medications. It is currently being debated in Congress, with supporters arguing that it is necessary to protect consumers from price gouging by pharmaceutical companies, while opponents raise concerns about potential negative impacts on innovation and research in the industry.
Congressional Summary of S 113
Prescription Pricing for the People Act of 2023
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices.
Read the Full Bill
Current Status of Bill S 113
Bill S 113 is currently in the status of Bill Introduced since January 26, 2023. Bill S 113 was introduced during Congress 118 and was introduced to the Senate on January 26, 2023. Bill S 113's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 19. as of March 1, 2023
Bipartisan Support of Bill S 113
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
40Democrat Cosponsors
18Republican Cosponsors
20Unaffiliated Cosponsors
2Policy Area and Potential Impact of Bill S 113
Primary Policy Focus
CommercePotential Impact Areas
- Business ethics
- Business records
- Competition and antitrust
- Congressional oversight
- Consumer affairs
- Health care costs and insurance
- Health information and medical records
- Inflation and prices
- Prescription drugs
- Retail and wholesale trades
Alternate Title(s) of Bill S 113
Prescription Pricing for the People Act of 2023
Prescription Pricing for the People Act of 2023
Prescription Pricing for the People Act of 2023
A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.
Comments
Sponsors and Cosponsors of S 113
Latest Bills
Supporting the goals and ideals of International Transgender Day of Visibility.
Bill HCONRES 82April 2, 2026
HERO Act
Bill HR 7994April 2, 2026
Vote Without Fear Act
Bill HR 7965April 2, 2026
Water Power Research and Development Reauthorization Act
Bill S 3684April 2, 2026
No Lifeline for the Dead Act
Bill HR 7963April 2, 2026
HBCU AI Research Leadership Act
Bill HR 7826April 2, 2026
Innovative Therapies Centers of Excellence Act
Bill S 4031April 2, 2026
A resolution designating the third week of March 2026 as "National CACFP Week".
Bill SRES 656April 2, 2026
A resolution recognizing the importance of the United States-Japan Alliance and welcoming the visit of Prime Minister Takaichi Sanae to the United States.
Bill SRES 652April 2, 2026
Restoring the Secondary Trading Market Act
Bill HR 7127April 2, 2026





